Abstract:Introduction & Objective: Artificial pancreas (AP) studies are upsurging, half of which were published in the last 5 years. We aimed to evaluate the efficacy and safety of AP in patients with type 1 diabetes (T1D). Methods: We searched PubMed, Embase, Cochrane Library, web of science and ClinicalTrials.gov from inception to August 31, 2023. Randomized clinical trials that compared artificial pancreas with other insulin-based treatments in patients with T1D were considered eligible. The primary outcome was percentage of time in range (TIR) (3.9-10.0 mmol/L). Secondary outcomes were other glycemic metrics derived from continuous glucose monitoring, HbA1c and insulin dose. Safety outcomes included the incidence of severe hypoglycemia and diabetic ketoacidosis. Results: A total of 3623 patients with 73 comparisons from 65 trials were included. The percentage of TIR was 11.74% (95% CI 9.37 to 14.12, P < 0.001) higher with AP compared with control treatments. Patients on AP had more pronounced improvement of time below range when diabetes duration was more than 20 years (-1.80% vs. -0.86%, P = 0.031) and baseline HbA1c lower than 7.5% (-1.93% vs. -0.87%, P = 0.033). Full closed-loop systems revealed a greater improvement in time above range compared with hybrid closed-loop systems (-15.53% vs. -9.22%, P = 0.020). Notably, glycemia risk index (GRI) (-3.74 [CI, -6.34 to -1.14], P < 0.01) was also improved with AP therapy. Conclusion: AP showed significant advantages compared to other insulin-based treatments in improving glucose control represented by TIR and GRI in patients with T1D, with more favorable effect in hyperglycemia by full closed-loop systems as well as less hypoglycemia for patients who are within target for glycemic control and have longer diabetes duration. W. Fan: None. C. Deng: None. R. Xu: None. Z. Liu: None. Z. Zhou: None. X. Li: None. the Unveiling and Leading Program of Hunan Province (2021JC0003), the Science and Technology Innovation Program of Hunan Province (2020RC4044), and the Sinocare Diabetes Foundation (2021SD06, LYF2022039)

Clinical application value and research progress of artificial pancreas closed-Loop control in diabctes mellitus

Recent advances in the precision control strategy of artificial pancreas

Progress of the Test and Assessment of Islet Β Cell Function

A Study of Methods for Predicting and Controlling Blood Glucose in Diabetic Patients

1900-LB: Efficacy and Safety of Artificial Pancreas in Patients with Type 1 Diabetes—A Systematic Review and Meta-analysis

Recent advancements in noninvasive glucose monitoring and closed-loop management systems for diabetes

BITAPS: A Mobile-Computing Assisted Ar Pancreas Systems Control Platform

Data-enabled Learning and Control Algorithms for Intelligent Glucose Management: the State of the Art

The artificial pancreas: two alternative approaches to achieve a fully closed-loop system with optimal glucose control

A novel pulse-modulated closed-loop artificial pancreas based on intravenous administration of insulin and glucagon

An event-triggered active disturbance rejection approach to dual-hormonal artificial pancreas control

A smart medical system for dynamic closed-loop blood glucose-insulin control

An Integrated Intelligent Insulin Pump

Glucose-Responsive Synthetic Closed-Loop Insulin Delivery Systems

Design and Validation of an Open-Source Closed-Loop Testbed for Artificial Pancreas Systems

An Adaptive Disturbance Rejection Controller for Artificial Pancreas

Recent advances in the smart insulin delivery systems for the treatment of diabetes

A comprehensive review of models and nonlinear control strategies for blood glucose regulation in artificial pancreas

Research progress of real-time continuous glucose monitoring technology

Research on Blood Glucose Nonlinear Controller Based on Backstepping Adaptive Control Algorithm

Multivariable Adaptive Artificial Pancreas System in Type 1 Diabetes